Selected research
Market Outlook & Growth Opportunities
Global RNA-Targeted Small Molecules Market Outlook and Growth Opportunities 2026
Market perspective
The global RNA-Targeted Small Molecules market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.
The North America market for RNA-Targeted Small Molecules is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for RNA-Targeted Small Molecules is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for RNA-Targeted Small Molecules is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
In China, the RNA-Targeted Small Molecules market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Major global companies in the RNA-Targeted Small Molecules market include Twentyeight-Seven Therapeutics, STORM Therapeutics, Skyhawk Therapeutics, Ribometrix, H3 Biomedicine, Gotham Therapeutics, Expansion Therapeutics, Epics Therapeutics and Arrakis Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.
This report provides an overview of the global RNA-Targeted Small Molecules market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of RNA-Targeted Small Molecules and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents RNA-Targeted Small Molecules revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global RNA-Targeted Small Molecules market.
RNA-Targeted Small Molecules Segment by Company
Twentyeight-Seven Therapeutics
STORM Therapeutics
Skyhawk Therapeutics
Ribometrix
H3 Biomedicine
Gotham Therapeutics
Expansion Therapeutics
Epics Therapeutics
Arrakis Pharmaceuticals
Anima Biotech Inc.
Accent Therapeutics
RNA-Targeted Small Molecules Segment by Type
mRNA Translation Regulation
RNA Splicing Modification
Indirect RNA Targeting - Epitranscriptomics
Direct RNA Targeting
RNA-Targeted Small Molecules Segment by Application
Laboratories
Hospitals
Phamacy
RNA-Targeted Small Molecules Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global RNA-Targeted Small Molecules status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the RNA-Targeted Small Molecules key companies, revenue, market share, and recent developments.
3. To split the RNA-Targeted Small Molecules breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions RNA-Targeted Small Molecules market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify RNA-Targeted Small Molecules significant trends, drivers, influence factors in global and regions.
6. To analyze RNA-Targeted Small Molecules competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global RNA-Targeted Small Molecules market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of RNA-Targeted Small Molecules and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of RNA-Targeted Small Molecules.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global RNA-Targeted Small Molecules industry.
Chapter 3: Detailed analysis of RNA-Targeted Small Molecules company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of RNA-Targeted Small Molecules in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of RNA-Targeted Small Molecules in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
More report detail
Tables and figures
List of Tables
Table 1. RNA-Targeted Small Molecules Industry Trends
Table 2. RNA-Targeted Small Molecules Industry Drivers
Table 3. RNA-Targeted Small Molecules Industry Opportunities and Challenges
Table 4. RNA-Targeted Small Molecules Industry Restraints
Table 5. Global RNA-Targeted Small Molecules Revenue by Company (US$ Million) & (2021-2026)
Table 6. Global RNA-Targeted Small Molecules Revenue Share by Company (2021-2026)
Table 7. Global RNA-Targeted Small Molecules Company Ranking, (2024-2026) & (US$ Million)
Table 8. Global RNA-Targeted Small Molecules Key Company Manufacturing Base & Headquarters
Table 9. Global RNA-Targeted Small Molecules Company, Product Type & Application
Table 10. Global RNA-Targeted Small Molecules Company Establishment Date
Table 11. Global Company Market Concentration Ratio (CR5 and HHI)
Table 12. Global RNA-Targeted Small Molecules by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025)
Table 13. Mergers & Acquisitions, Expansion
Table 14. Significant Companies of mRNA Translation Regulation
Table 15. Significant Companies of RNA Splicing Modification
Table 16. Significant Companies of Indirect RNA Targeting - Epitranscriptomics
Table 17. Significant Companies of Direct RNA Targeting
Table 18. Global RNA-Targeted Small Molecules Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million)
Table 19. Global RNA-Targeted Small Molecules Sales Value by Type (2021-2026) & (US$ Million)
Table 20. Global RNA-Targeted Small Molecules Sales Value by Type (2027-2032) & (US$ Million)
Table 21. Global RNA-Targeted Small Molecules Sales Value Share by Type (2021-2026)
Table 22. Global RNA-Targeted Small Molecules Sales Value Share by Type (2027-2032)
Table 23. Significant Companies of Laboratories
Table 24. Significant Companies of Hospitals
Table 25. Significant Companies of Phamacy
Table 26. Global RNA-Targeted Small Molecules Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million)
Table 27. Global RNA-Targeted Small Molecules Sales Value by Application (2021-2026) & (US$ Million)
Table 28. Global RNA-Targeted Small Molecules Sales Value by Application (2027-2032) & (US$ Million)
Table 29. Global RNA-Targeted Small Molecules Sales Value Share by Application (2021-2026)
Table 30. Global RNA-Targeted Small Molecules Sales Value Share by Application (2027-2032)
Table 31. Global RNA-Targeted Small Molecules Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million)
Table 32. Global RNA-Targeted Small Molecules Sales Value by Region (2021-2026) & (US$ Million)
Table 33. Global RNA-Targeted Small Molecules Sales Value Share by Region (2021-2026)
Table 34. Global RNA-Targeted Small Molecules Sales Value by Region (2027-2032) & (US$ Million)
Table 35. Global RNA-Targeted Small Molecules Sales Value Share by Region (2027-2032)
Table 36. Global RNA-Targeted Small Molecules Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 37. Global RNA-Targeted Small Molecules Sales Value by Country (2021-2026) & (US$ Million)
Table 38. Global RNA-Targeted Small Molecules Sales Value Market Share by Country (2021-2026)
Table 39. Global RNA-Targeted Small Molecules Sales Value by Country (2027-2032) & (US$ Million)
Table 40. Global RNA-Targeted Small Molecules Sales Value Market Share by Country (2027-2032)
Table 41. Twentyeight-Seven Therapeutics Company Information
Table 42. Twentyeight-Seven Therapeutics Business Overview
Table 43. Twentyeight-Seven Therapeutics RNA-Targeted Small Molecules Revenue (US$ Million) and Gross Margin (2021-2026)
Table 44. Twentyeight-Seven Therapeutics RNA-Targeted Small Molecules Product Portfolio
Table 45. Twentyeight-Seven Therapeutics Recent Development
Table 46. STORM Therapeutics Company Information
Table 47. STORM Therapeutics Business Overview
Table 48. STORM Therapeutics RNA-Targeted Small Molecules Revenue (US$ Million) and Gross Margin (2021-2026)
Table 49. STORM Therapeutics RNA-Targeted Small Molecules Product Portfolio
Table 50. STORM Therapeutics Recent Development
Table 51. Skyhawk Therapeutics Company Information
Table 52. Skyhawk Therapeutics Business Overview
Table 53. Skyhawk Therapeutics RNA-Targeted Small Molecules Revenue (US$ Million) and Gross Margin (2021-2026)
Table 54. Skyhawk Therapeutics RNA-Targeted Small Molecules Product Portfolio
Table 55. Skyhawk Therapeutics Recent Development
Table 56. Ribometrix Company Information
Table 57. Ribometrix Business Overview
Table 58. Ribometrix RNA-Targeted Small Molecules Revenue (US$ Million) and Gross Margin (2021-2026)
Table 59. Ribometrix RNA-Targeted Small Molecules Product Portfolio
Table 60. Ribometrix Recent Development
Table 61. H3 Biomedicine Company Information
Table 62. H3 Biomedicine Business Overview
Table 63. H3 Biomedicine RNA-Targeted Small Molecules Revenue (US$ Million) and Gross Margin (2021-2026)
Table 64. H3 Biomedicine RNA-Targeted Small Molecules Product Portfolio
Table 65. H3 Biomedicine Recent Development
Table 66. Gotham Therapeutics Company Information
Table 67. Gotham Therapeutics Business Overview
Table 68. Gotham Therapeutics RNA-Targeted Small Molecules Revenue (US$ Million) and Gross Margin (2021-2026)
Table 69. Gotham Therapeutics RNA-Targeted Small Molecules Product Portfolio
Table 70. Gotham Therapeutics Recent Development
Table 71. Expansion Therapeutics Company Information
Table 72. Expansion Therapeutics Business Overview
Table 73. Expansion Therapeutics RNA-Targeted Small Molecules Revenue (US$ Million) and Gross Margin (2021-2026)
Table 74. Expansion Therapeutics RNA-Targeted Small Molecules Product Portfolio
Table 75. Expansion Therapeutics Recent Development
Table 76. Epics Therapeutics Company Information
Table 77. Epics Therapeutics Business Overview
Table 78. Epics Therapeutics RNA-Targeted Small Molecules Revenue (US$ Million) and Gross Margin (2021-2026)
Table 79. Epics Therapeutics RNA-Targeted Small Molecules Product Portfolio
Table 80. Epics Therapeutics Recent Development
Table 81. Arrakis Pharmaceuticals Company Information
Table 82. Arrakis Pharmaceuticals Business Overview
Table 83. Arrakis Pharmaceuticals RNA-Targeted Small Molecules Revenue (US$ Million) and Gross Margin (2021-2026)
Table 84. Arrakis Pharmaceuticals RNA-Targeted Small Molecules Product Portfolio
Table 85. Arrakis Pharmaceuticals Recent Development
Table 86. Anima Biotech Inc. Company Information
Table 87. Anima Biotech Inc. Business Overview
Table 88. Anima Biotech Inc. RNA-Targeted Small Molecules Revenue (US$ Million) and Gross Margin (2021-2026)
Table 89. Anima Biotech Inc. RNA-Targeted Small Molecules Product Portfolio
Table 90. Anima Biotech Inc. Recent Development
Table 91. Accent Therapeutics Company Information
Table 92. Accent Therapeutics Business Overview
Table 93. Accent Therapeutics RNA-Targeted Small Molecules Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 94. Accent Therapeutics RNA-Targeted Small Molecules Product Portfolio
Table 95. Accent Therapeutics Recent Development
Table 96. Research Programs/Design for This Report
Table 97. Authors List of This Report
Table 98. Secondary Sources
Table 99. Primary Sources
List of Figures
Figure 1. RNA-Targeted Small Molecules Product Image
Figure 2. Global RNA-Targeted Small Molecules Market Size (US$ Million), 2021 VS 2025 VS 2032
Figure 3. Global RNA-Targeted Small Molecules Market Size (2021-2032) & (US$ Million)
Figure 4. Global RNA-Targeted Small Molecules Company Revenue Ranking in 2025 (US$ Million)
Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million)
Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
Figure 7. mRNA Translation Regulation Image
Figure 8. RNA Splicing Modification Image
Figure 9. Indirect RNA Targeting - Epitranscriptomics Image
Figure 10. Direct RNA Targeting Image
Figure 11. Global RNA-Targeted Small Molecules Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million)
Figure 12. Global RNA-Targeted Small Molecules Sales Value Share 2021 VS 2025 VS 2032
Figure 13. Global RNA-Targeted Small Molecules Sales Value Share by Type (2021-2032)
Figure 14. Laboratories Image
Figure 15. Hospitals Image
Figure 16. Phamacy Image
Figure 17. Global RNA-Targeted Small Molecules Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million)
Figure 18. Global RNA-Targeted Small Molecules Sales Value Share 2021 VS 2025 VS 2032
Figure 19. Global RNA-Targeted Small Molecules Sales Value Share by Application (2021-2032)
Figure 20. Global RNA-Targeted Small Molecules Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million)
Figure 21. Global RNA-Targeted Small Molecules Sales Value Share by Region: 2021 VS 2025 VS 2032
Figure 22. North America RNA-Targeted Small Molecules Sales Value (2021-2032) & (US$ Million)
Figure 23. North America RNA-Targeted Small Molecules Sales Value Share by Country (%), 2025 VS 2032
Figure 24. Europe RNA-Targeted Small Molecules Sales Value (2021-2032) & (US$ Million)
Figure 25. Europe RNA-Targeted Small Molecules Sales Value Share by Country (%), 2025 VS 2032
Figure 26. Asia-Pacific RNA-Targeted Small Molecules Sales Value (2021-2032) & (US$ Million)
Figure 27. Asia-Pacific RNA-Targeted Small Molecules Sales Value Share by Country (%), 2025 VS 2032
Figure 28. South America RNA-Targeted Small Molecules Sales Value (2021-2032) & (US$ Million)
Figure 29. South America RNA-Targeted Small Molecules Sales Value Share by Country (%), 2025 VS 2032
Figure 30. Middle East & Africa RNA-Targeted Small Molecules Sales Value (2021-2032) & (US$ Million)
Figure 31. Middle East & Africa RNA-Targeted Small Molecules Sales Value Share by Country (%), 2025 VS 2032
Figure 32. USA RNA-Targeted Small Molecules Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 33. USA RNA-Targeted Small Molecules Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 34. USA RNA-Targeted Small Molecules Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 35. Canada RNA-Targeted Small Molecules Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 36. Canada RNA-Targeted Small Molecules Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 37. Canada RNA-Targeted Small Molecules Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 38. Mexico RNA-Targeted Small Molecules Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 39. Mexico RNA-Targeted Small Molecules Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 40. Mexico RNA-Targeted Small Molecules Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 41. Germany RNA-Targeted Small Molecules Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 42. Germany RNA-Targeted Small Molecules Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 43. Germany RNA-Targeted Small Molecules Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 44. France RNA-Targeted Small Molecules Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 45. France RNA-Targeted Small Molecules Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 46. France RNA-Targeted Small Molecules Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 47. U.K. RNA-Targeted Small Molecules Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 48. U.K. RNA-Targeted Small Molecules Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 49. U.K. RNA-Targeted Small Molecules Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 50. Italy RNA-Targeted Small Molecules Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 51. Italy RNA-Targeted Small Molecules Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 52. Italy RNA-Targeted Small Molecules Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 53. Spain RNA-Targeted Small Molecules Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 54. Spain RNA-Targeted Small Molecules Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 55. Spain RNA-Targeted Small Molecules Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 56. Russia RNA-Targeted Small Molecules Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 57. Russia RNA-Targeted Small Molecules Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 58. Russia RNA-Targeted Small Molecules Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 59. Netherlands RNA-Targeted Small Molecules Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 60. Netherlands RNA-Targeted Small Molecules Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 61. Netherlands RNA-Targeted Small Molecules Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 62. Nordic Countries RNA-Targeted Small Molecules Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 63. Nordic Countries RNA-Targeted Small Molecules Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 64. Nordic Countries RNA-Targeted Small Molecules Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 65. China RNA-Targeted Small Molecules Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 66. China RNA-Targeted Small Molecules Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 67. China RNA-Targeted Small Molecules Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 68. Japan RNA-Targeted Small Molecules Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 69. Japan RNA-Targeted Small Molecules Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 70. Japan RNA-Targeted Small Molecules Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 71. South Korea RNA-Targeted Small Molecules Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 72. South Korea RNA-Targeted Small Molecules Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 73. South Korea RNA-Targeted Small Molecules Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 74. India RNA-Targeted Small Molecules Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 75. India RNA-Targeted Small Molecules Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 76. India RNA-Targeted Small Molecules Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 77. Australia RNA-Targeted Small Molecules Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 78. Australia RNA-Targeted Small Molecules Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 79. Australia RNA-Targeted Small Molecules Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 80. Southeast Asia RNA-Targeted Small Molecules Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 81. Southeast Asia RNA-Targeted Small Molecules Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 82. Southeast Asia RNA-Targeted Small Molecules Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 83. Brazil RNA-Targeted Small Molecules Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 84. Brazil RNA-Targeted Small Molecules Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 85. Brazil RNA-Targeted Small Molecules Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 86. Argentina RNA-Targeted Small Molecules Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 87. Argentina RNA-Targeted Small Molecules Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 88. Argentina RNA-Targeted Small Molecules Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 89. Chile RNA-Targeted Small Molecules Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 90. Chile RNA-Targeted Small Molecules Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 91. Chile RNA-Targeted Small Molecules Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 92. Colombia RNA-Targeted Small Molecules Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 93. Colombia RNA-Targeted Small Molecules Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 94. Colombia RNA-Targeted Small Molecules Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 95. Peru RNA-Targeted Small Molecules Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 96. Peru RNA-Targeted Small Molecules Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 97. Peru RNA-Targeted Small Molecules Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 98. Saudi Arabia RNA-Targeted Small Molecules Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 99. Saudi Arabia RNA-Targeted Small Molecules Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 100. Saudi Arabia RNA-Targeted Small Molecules Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 101. Israel RNA-Targeted Small Molecules Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 102. Israel RNA-Targeted Small Molecules Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 103. Israel RNA-Targeted Small Molecules Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 104. UAE RNA-Targeted Small Molecules Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 105. UAE RNA-Targeted Small Molecules Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 106. UAE RNA-Targeted Small Molecules Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 107. Turkey RNA-Targeted Small Molecules Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 108. Turkey RNA-Targeted Small Molecules Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 109. Turkey RNA-Targeted Small Molecules Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 110. Iran RNA-Targeted Small Molecules Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 111. Iran RNA-Targeted Small Molecules Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 112. Iran RNA-Targeted Small Molecules Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 113. Egypt RNA-Targeted Small Molecules Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 114. Egypt RNA-Targeted Small Molecules Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 115. Egypt RNA-Targeted Small Molecules Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 116. Years Considered
Figure 117. Research Process
Figure 118. Key Executives Interviewed
Scope & coverage.
Types
- mRNA Translation Regulation
- RNA Splicing Modification
- Indirect RNA Targeting - Epitranscriptomics
- Direct RNA Targeting
Applications
- Laboratories
- Hospitals
- Phamacy
Companies covered
- Twentyeight-Seven Therapeutics
- STORM Therapeutics
- Skyhawk Therapeutics
- Ribometrix
- H3 Biomedicine
- Gotham Therapeutics
- Expansion Therapeutics
- Epics Therapeutics
- Arrakis Pharmaceuticals
- Anima Biotech Inc.
- Accent Therapeutics
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global RNA-Targeted Small Molecules Market Size, 2021 VS 2025 VS 2032
- 1.3 Global RNA-Targeted Small Molecules Market Size (2021-2032)
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 RNA-Targeted Small Molecules Market Dynamics
- 2.1 RNA-Targeted Small Molecules Industry Trends
- 2.2 RNA-Targeted Small Molecules Industry Drivers
- 2.3 RNA-Targeted Small Molecules Industry Opportunities and Challenges
- 2.4 RNA-Targeted Small Molecules Industry Restraints
3 RNA-Targeted Small Molecules Market by Company
- 3.1 Global RNA-Targeted Small Molecules Company Revenue Ranking in 2025
- 3.2 Global RNA-Targeted Small Molecules Revenue by Company (2021-2026)
- 3.3 Global RNA-Targeted Small Molecules Company Ranking (2024-2026)
- 3.4 Global RNA-Targeted Small Molecules Company Manufacturing Base and Headquarters
- 3.5 Global RNA-Targeted Small Molecules Company Product Type and Application
- 3.6 Global RNA-Targeted Small Molecules Company Establishment Date
- 3.7 Market Competitive Analysis
- 3.7.1 Global RNA-Targeted Small Molecules Market Concentration Ratio (CR5 and HHI)
- 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
- 3.7.3 2025 RNA-Targeted Small Molecules Tier 1, Tier 2, and Tier 3 Companies
- 3.8 Mergers and Acquisitions Expansion
4 RNA-Targeted Small Molecules Market by Type
- 4.1 RNA-Targeted Small Molecules Type Introduction
- 4.1.1 mRNA Translation Regulation
- 4.1.2 RNA Splicing Modification
- 4.1.3 Indirect RNA Targeting - Epitranscriptomics
- 4.1.4 Direct RNA Targeting
- 4.2 Global RNA-Targeted Small Molecules Sales Value by Type
- 4.2.1 Global RNA-Targeted Small Molecules Sales Value by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global RNA-Targeted Small Molecules Sales Value by Type (2021-2032)
- 4.2.3 Global RNA-Targeted Small Molecules Sales Value Share by Type (2021-2032)
5 RNA-Targeted Small Molecules Market by Application
- 5.1 RNA-Targeted Small Molecules Application Introduction
- 5.1.1 Laboratories
- 5.1.2 Hospitals
- 5.1.3 Phamacy
- 5.2 Global RNA-Targeted Small Molecules Sales Value by Application
- 5.2.1 Global RNA-Targeted Small Molecules Sales Value by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global RNA-Targeted Small Molecules Sales Value by Application (2021-2032)
- 5.2.3 Global RNA-Targeted Small Molecules Sales Value Share by Application (2021-2032)
6 RNA-Targeted Small Molecules Regional Value Analysis
- 6.1 Global RNA-Targeted Small Molecules Sales Value by Region: 2021 VS 2025 VS 2032
- 6.2 Global RNA-Targeted Small Molecules Sales Value by Region (2021-2032)
- 6.2.1 Global RNA-Targeted Small Molecules Sales Value by Region: 2021-2026
- 6.2.2 Global RNA-Targeted Small Molecules Sales Value by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America RNA-Targeted Small Molecules Sales Value (2021-2032)
- 6.3.2 North America RNA-Targeted Small Molecules Sales Value Share by Country, 2025 VS 2032
- 6.4 Europe
- 6.4.1 Europe RNA-Targeted Small Molecules Sales Value (2021-2032)
- 6.4.2 Europe RNA-Targeted Small Molecules Sales Value Share by Country, 2025 VS 2032
- 6.5 Asia-Pacific
- 6.5.1 Asia-Pacific RNA-Targeted Small Molecules Sales Value (2021-2032)
- 6.5.2 Asia-Pacific RNA-Targeted Small Molecules Sales Value Share by Country, 2025 VS 2032
- 6.6 South America
- 6.6.1 South America RNA-Targeted Small Molecules Sales Value (2021-2032)
- 6.6.2 South America RNA-Targeted Small Molecules Sales Value Share by Country, 2025 VS 2032
- 6.7 Middle East & Africa
- 6.7.1 Middle East & Africa RNA-Targeted Small Molecules Sales Value (2021-2032)
- 6.7.2 Middle East & Africa RNA-Targeted Small Molecules Sales Value Share by Country, 2025 VS 2032
7 RNA-Targeted Small Molecules Country-level Value Analysis
- 7.1 Global RNA-Targeted Small Molecules Sales Value by Country: 2021 VS 2025 VS 2032
- 7.2 Global RNA-Targeted Small Molecules Sales Value by Country (2021-2032)
- 7.2.1 Global RNA-Targeted Small Molecules Sales Value by Country (2021-2026)
- 7.2.2 Global RNA-Targeted Small Molecules Sales Value by Country (2027-2032)
- 7.3 USA
- 7.3.1 USA RNA-Targeted Small Molecules Sales Value Growth Rate (2021-2032)
- 7.3.2 USA RNA-Targeted Small Molecules Sales Value Share by Type, 2025 VS 2032
- 7.3.3 USA RNA-Targeted Small Molecules Sales Value Share by Application, 2025 VS 2032
- 7.4 Canada
- 7.4.1 Canada RNA-Targeted Small Molecules Sales Value Growth Rate (2021-2032)
- 7.4.2 Canada RNA-Targeted Small Molecules Sales Value Share by Type, 2025 VS 2032
- 7.4.3 Canada RNA-Targeted Small Molecules Sales Value Share by Application, 2025 VS 2032
- 7.5 Mexico
- 7.5.1 Mexico RNA-Targeted Small Molecules Sales Value Growth Rate (2021-2032)
- 7.5.2 Mexico RNA-Targeted Small Molecules Sales Value Share by Type, 2025 VS 2032
- 7.5.3 Mexico RNA-Targeted Small Molecules Sales Value Share by Application, 2025 VS 2032
- 7.6 Germany
- 7.6.1 Germany RNA-Targeted Small Molecules Sales Value Growth Rate (2021-2032)
- 7.6.2 Germany RNA-Targeted Small Molecules Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Germany RNA-Targeted Small Molecules Sales Value Share by Application, 2025 VS 2032
- 7.7 France
- 7.7.1 France RNA-Targeted Small Molecules Sales Value Growth Rate (2021-2032)
- 7.7.2 France RNA-Targeted Small Molecules Sales Value Share by Type, 2025 VS 2032
- 7.7.3 France RNA-Targeted Small Molecules Sales Value Share by Application, 2025 VS 2032
- 7.8 U.K.
- 7.8.1 U.K. RNA-Targeted Small Molecules Sales Value Growth Rate (2021-2032)
- 7.8.2 U.K. RNA-Targeted Small Molecules Sales Value Share by Type, 2025 VS 2032
- 7.8.3 U.K. RNA-Targeted Small Molecules Sales Value Share by Application, 2025 VS 2032
- 7.9 Italy
- 7.9.1 Italy RNA-Targeted Small Molecules Sales Value Growth Rate (2021-2032)
- 7.9.2 Italy RNA-Targeted Small Molecules Sales Value Share by Type, 2025 VS 2032
- 7.9.3 Italy RNA-Targeted Small Molecules Sales Value Share by Application, 2025 VS 2032
- 7.10 Spain
- 7.10.1 Spain RNA-Targeted Small Molecules Sales Value Growth Rate (2021-2032)
- 7.10.2 Spain RNA-Targeted Small Molecules Sales Value Share by Type, 2025 VS 2032
- 7.10.3 Spain RNA-Targeted Small Molecules Sales Value Share by Application, 2025 VS 2032
- 7.11 Russia
- 7.11.1 Russia RNA-Targeted Small Molecules Sales Value Growth Rate (2021-2032)
- 7.11.2 Russia RNA-Targeted Small Molecules Sales Value Share by Type, 2025 VS 2032
- 7.11.3 Russia RNA-Targeted Small Molecules Sales Value Share by Application, 2025 VS 2032
- 7.12 Netherlands
- 7.12.1 Netherlands RNA-Targeted Small Molecules Sales Value Growth Rate (2021-2032)
- 7.12.2 Netherlands RNA-Targeted Small Molecules Sales Value Share by Type, 2025 VS 2032
- 7.12.3 Netherlands RNA-Targeted Small Molecules Sales Value Share by Application, 2025 VS 2032
- 7.13 Nordic Countries
- 7.13.1 Nordic Countries RNA-Targeted Small Molecules Sales Value Growth Rate (2021-2032)
- 7.13.2 Nordic Countries RNA-Targeted Small Molecules Sales Value Share by Type, 2025 VS 2032
- 7.13.3 Nordic Countries RNA-Targeted Small Molecules Sales Value Share by Application, 2025 VS 2032
- 7.14 China
- 7.14.1 China RNA-Targeted Small Molecules Sales Value Growth Rate (2021-2032)
- 7.14.2 China RNA-Targeted Small Molecules Sales Value Share by Type, 2025 VS 2032
- 7.14.3 China RNA-Targeted Small Molecules Sales Value Share by Application, 2025 VS 2032
- 7.15 Japan
- 7.15.1 Japan RNA-Targeted Small Molecules Sales Value Growth Rate (2021-2032)
- 7.15.2 Japan RNA-Targeted Small Molecules Sales Value Share by Type, 2025 VS 2032
- 7.15.3 Japan RNA-Targeted Small Molecules Sales Value Share by Application, 2025 VS 2032
- 7.16 South Korea
- 7.16.1 South Korea RNA-Targeted Small Molecules Sales Value Growth Rate (2021-2032)
- 7.16.2 South Korea RNA-Targeted Small Molecules Sales Value Share by Type, 2025 VS 2032
- 7.16.3 South Korea RNA-Targeted Small Molecules Sales Value Share by Application, 2025 VS 2032
- 7.17 India
- 7.17.1 India RNA-Targeted Small Molecules Sales Value Growth Rate (2021-2032)
- 7.17.2 India RNA-Targeted Small Molecules Sales Value Share by Type, 2025 VS 2032
- 7.17.3 India RNA-Targeted Small Molecules Sales Value Share by Application, 2025 VS 2032
- 7.18 Australia
- 7.18.1 Australia RNA-Targeted Small Molecules Sales Value Growth Rate (2021-2032)
- 7.18.2 Australia RNA-Targeted Small Molecules Sales Value Share by Type, 2025 VS 2032
- 7.18.3 Australia RNA-Targeted Small Molecules Sales Value Share by Application, 2025 VS 2032
- 7.19 Southeast Asia
- 7.19.1 Southeast Asia RNA-Targeted Small Molecules Sales Value Growth Rate (2021-2032)
- 7.19.2 Southeast Asia RNA-Targeted Small Molecules Sales Value Share by Type, 2025 VS 2032
- 7.19.3 Southeast Asia RNA-Targeted Small Molecules Sales Value Share by Application, 2025 VS 2032
- 7.20 Brazil
- 7.20.1 Brazil RNA-Targeted Small Molecules Sales Value Growth Rate (2021-2032)
- 7.20.2 Brazil RNA-Targeted Small Molecules Sales Value Share by Type, 2025 VS 2032
- 7.20.3 Brazil RNA-Targeted Small Molecules Sales Value Share by Application, 2025 VS 2032
- 7.21 Argentina
- 7.21.1 Argentina RNA-Targeted Small Molecules Sales Value Growth Rate (2021-2032)
- 7.21.2 Argentina RNA-Targeted Small Molecules Sales Value Share by Type, 2025 VS 2032
- 7.21.3 Argentina RNA-Targeted Small Molecules Sales Value Share by Application, 2025 VS 2032
- 7.22 Chile
- 7.22.1 Chile RNA-Targeted Small Molecules Sales Value Growth Rate (2021-2032)
- 7.22.2 Chile RNA-Targeted Small Molecules Sales Value Share by Type, 2025 VS 2032
- 7.22.3 Chile RNA-Targeted Small Molecules Sales Value Share by Application, 2025 VS 2032
- 7.23 Colombia
- 7.23.1 Colombia RNA-Targeted Small Molecules Sales Value Growth Rate (2021-2032)
- 7.23.2 Colombia RNA-Targeted Small Molecules Sales Value Share by Type, 2025 VS 2032
- 7.23.3 Colombia RNA-Targeted Small Molecules Sales Value Share by Application, 2025 VS 2032
- 7.24 Peru
- 7.24.1 Peru RNA-Targeted Small Molecules Sales Value Growth Rate (2021-2032)
- 7.24.2 Peru RNA-Targeted Small Molecules Sales Value Share by Type, 2025 VS 2032
- 7.24.3 Peru RNA-Targeted Small Molecules Sales Value Share by Application, 2025 VS 2032
- 7.25 Saudi Arabia
- 7.25.1 Saudi Arabia RNA-Targeted Small Molecules Sales Value Growth Rate (2021-2032)
- 7.25.2 Saudi Arabia RNA-Targeted Small Molecules Sales Value Share by Type, 2025 VS 2032
- 7.25.3 Saudi Arabia RNA-Targeted Small Molecules Sales Value Share by Application, 2025 VS 2032
- 7.26 Israel
- 7.26.1 Israel RNA-Targeted Small Molecules Sales Value Growth Rate (2021-2032)
- 7.26.2 Israel RNA-Targeted Small Molecules Sales Value Share by Type, 2025 VS 2032
- 7.26.3 Israel RNA-Targeted Small Molecules Sales Value Share by Application, 2025 VS 2032
- 7.27 UAE
- 7.27.1 UAE RNA-Targeted Small Molecules Sales Value Growth Rate (2021-2032)
- 7.27.2 UAE RNA-Targeted Small Molecules Sales Value Share by Type, 2025 VS 2032
- 7.27.3 UAE RNA-Targeted Small Molecules Sales Value Share by Application, 2025 VS 2032
- 7.28 Turkey
- 7.28.1 Turkey RNA-Targeted Small Molecules Sales Value Growth Rate (2021-2032)
- 7.28.2 Turkey RNA-Targeted Small Molecules Sales Value Share by Type, 2025 VS 2032
- 7.28.3 Turkey RNA-Targeted Small Molecules Sales Value Share by Application, 2025 VS 2032
- 7.29 Iran
- 7.29.1 Iran RNA-Targeted Small Molecules Sales Value Growth Rate (2021-2032)
- 7.29.2 Iran RNA-Targeted Small Molecules Sales Value Share by Type, 2025 VS 2032
- 7.29.3 Iran RNA-Targeted Small Molecules Sales Value Share by Application, 2025 VS 2032
- 7.30 Egypt
- 7.30.1 Egypt RNA-Targeted Small Molecules Sales Value Growth Rate (2021-2032)
- 7.30.2 Egypt RNA-Targeted Small Molecules Sales Value Share by Type, 2025 VS 2032
- 7.30.3 Egypt RNA-Targeted Small Molecules Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
- 8.1 Twentyeight-Seven Therapeutics
- 8.1.1 Twentyeight-Seven Therapeutics Company Information
- 8.1.2 Twentyeight-Seven Therapeutics Business Overview
- 8.1.3 Twentyeight-Seven Therapeutics RNA-Targeted Small Molecules Revenue and Gross Margin (2021-2026)
- 8.1.4 Twentyeight-Seven Therapeutics RNA-Targeted Small Molecules Product Portfolio
- 8.1.5 Twentyeight-Seven Therapeutics Recent Developments
- 8.2 STORM Therapeutics
- 8.2.1 STORM Therapeutics Company Information
- 8.2.2 STORM Therapeutics Business Overview
- 8.2.3 STORM Therapeutics RNA-Targeted Small Molecules Revenue and Gross Margin (2021-2026)
- 8.2.4 STORM Therapeutics RNA-Targeted Small Molecules Product Portfolio
- 8.2.5 STORM Therapeutics Recent Developments
- 8.3 Skyhawk Therapeutics
- 8.3.1 Skyhawk Therapeutics Company Information
- 8.3.2 Skyhawk Therapeutics Business Overview
- 8.3.3 Skyhawk Therapeutics RNA-Targeted Small Molecules Revenue and Gross Margin (2021-2026)
- 8.3.4 Skyhawk Therapeutics RNA-Targeted Small Molecules Product Portfolio
- 8.3.5 Skyhawk Therapeutics Recent Developments
- 8.4 Ribometrix
- 8.4.1 Ribometrix Company Information
- 8.4.2 Ribometrix Business Overview
- 8.4.3 Ribometrix RNA-Targeted Small Molecules Revenue and Gross Margin (2021-2026)
- 8.4.4 Ribometrix RNA-Targeted Small Molecules Product Portfolio
- 8.4.5 Ribometrix Recent Developments
- 8.5 H3 Biomedicine
- 8.5.1 H3 Biomedicine Company Information
- 8.5.2 H3 Biomedicine Business Overview
- 8.5.3 H3 Biomedicine RNA-Targeted Small Molecules Revenue and Gross Margin (2021-2026)
- 8.5.4 H3 Biomedicine RNA-Targeted Small Molecules Product Portfolio
- 8.5.5 H3 Biomedicine Recent Developments
- 8.6 Gotham Therapeutics
- 8.6.1 Gotham Therapeutics Company Information
- 8.6.2 Gotham Therapeutics Business Overview
- 8.6.3 Gotham Therapeutics RNA-Targeted Small Molecules Revenue and Gross Margin (2021-2026)
- 8.6.4 Gotham Therapeutics RNA-Targeted Small Molecules Product Portfolio
- 8.6.5 Gotham Therapeutics Recent Developments
- 8.7 Expansion Therapeutics
- 8.7.1 Expansion Therapeutics Company Information
- 8.7.2 Expansion Therapeutics Business Overview
- 8.7.3 Expansion Therapeutics RNA-Targeted Small Molecules Revenue and Gross Margin (2021-2026)
- 8.7.4 Expansion Therapeutics RNA-Targeted Small Molecules Product Portfolio
- 8.7.5 Expansion Therapeutics Recent Developments
- 8.8 Epics Therapeutics
- 8.8.1 Epics Therapeutics Company Information
- 8.8.2 Epics Therapeutics Business Overview
- 8.8.3 Epics Therapeutics RNA-Targeted Small Molecules Revenue and Gross Margin (2021-2026)
- 8.8.4 Epics Therapeutics RNA-Targeted Small Molecules Product Portfolio
- 8.8.5 Epics Therapeutics Recent Developments
- 8.9 Arrakis Pharmaceuticals
- 8.9.1 Arrakis Pharmaceuticals Company Information
- 8.9.2 Arrakis Pharmaceuticals Business Overview
- 8.9.3 Arrakis Pharmaceuticals RNA-Targeted Small Molecules Revenue and Gross Margin (2021-2026)
- 8.9.4 Arrakis Pharmaceuticals RNA-Targeted Small Molecules Product Portfolio
- 8.9.5 Arrakis Pharmaceuticals Recent Developments
- 8.10 Anima Biotech Inc.
- 8.10.1 Anima Biotech Inc. Company Information
- 8.10.2 Anima Biotech Inc. Business Overview
- 8.10.3 Anima Biotech Inc. RNA-Targeted Small Molecules Revenue and Gross Margin (2021-2026)
- 8.10.4 Anima Biotech Inc. RNA-Targeted Small Molecules Product Portfolio
- 8.10.5 Anima Biotech Inc. Recent Developments
- 8.11 Accent Therapeutics
- 8.11.1 Accent Therapeutics Company Information
- 8.11.2 Accent Therapeutics Business Overview
- 8.11.3 Accent Therapeutics RNA-Targeted Small Molecules Revenue and Gross Margin (2021-2026)
- 8.11.4 Accent Therapeutics RNA-Targeted Small Molecules Product Portfolio
- 8.11.5 Accent Therapeutics Recent Developments
9 Concluding Insights
10 Appendix
- 10.1 Reasons for Doing This Study
- 10.2 Research Methodology
- 10.3 Research Process
- 10.4 Authors List of This Report
- 10.5 Data Source
- 10.5.1 Secondary Sources
- 10.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
$4,250USD
Buy nowPDF by email within 3–5 working days after payment confirmation.
Talk to an analyst